reports
Close Concerns is pleased to announce Diabetes Roundup II, a unique 400+ page compilation of observations on the diabetes and obesity industries - a followup to our Diabetes Roundup I, published in 2004. Diabetes Round Up II features:
- In-depth reviews of the top eight academic diabetes conferences over the last 18 months (ADA, ADA Postgraduate Sessions, AADE, AACE, EASD, DTT, NAASO, the 1st Annual Amsterdam Diabetes Forum)
- Detailed insights on the dozen additional conferences of note (Canadian Diabetes Association; 1st International Conference on Pre-Diabetes and the Metabolic Syndrome; AIDPIT: Artificial Insulin Delivery Systems, Pancreas, and Islet Transplantation; ACE/AACE Consensus Conference on Inpatient Diabetes and Glycemic Control; and the Levine Symposium, among others)
- Detailed financial models for the $6 billion blood glucose monitoring and $1 billion insulin pump markets
- An-depth drug pipeline database of 50-plus companies developing nearly 200 diabetes and obesity therapies
- Our selection of the top 50 diabetes-related articles in medical journals over the last year (JAMA, NEJM, Diabetes Care, The Diabetes Educator) and detailed reviews of each
- Our reports on the major analyst meetings over the last 12-18 months (Animas, BMS, Lilly, Medtronic, Merck, Roche, Pfizer, Sanofi, Mannkind)
- A detailed calendar of 30 important upcoming diabetes meetings in 2006 and 2007
- The best of DCU: our top five stories from DCU #1 - #55
- The Close Concerns High Five Awards: our detailed assessment of the top five diabetes products introduced over the last 12-18 months.
Who will benefit?
- Professionals in business development, strategic planning, or marketing in companies with interests in diabetes or obesity. Diabetes Roundup II will broaden its readers understanding of what is happening across the medical technology, pharmaceutical, and biotech industries.
- Investors seeking a better understanding of the opportunities in diabetes and obesity.
Diabetes Roundup Testimonial:
- "Diabetes Roundup provides an in-depth look at what has happened (and what is happening) in the diabetes 'space' over the last year. Kelly Close has synthesized a huge amount of information from multiple meetings, conferences, and key papers into a current and relevant view that is tempered by the perspective of both the analyst and a passionate consumer. This is valuable reading, particularly if you are trying to catch up on the field." Alan C. Moses, MD, Associate VP of Medical Affairs, Novo Nordisk Pharmaceuticals, Inc